{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:08Z","timestamp":1793823968024,"version":"4.6.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"US National Cancer Institute SPORE","award":["1P50CA265793"],"award-info":[{"award-number":["1P50CA265793"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Global incidence and mortality rates for endometrial and cervical cancers have been steadily rising, while these rates for ovarian cancer have decreased. Although these cancers represent unique diseases and challenges, overlapping biology and responses to targeted therapies and immunotherapies create opportunities to advance research through shared knowledge and resources. In 2025, investigators funded by US National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) and other NCI-supported grants convened a hybrid meeting to identify challenges and knowledge gaps in translational research, highlight advances, define shareable resources and technologies, and foster collaboration among the Gynecologic Cancer SPORE sites, patient advocates, and NCI staff. Special sessions were arranged for presentations by patient advocates, early-stage investigators, and investigators transitioning to gynecologic cancer research. Meeting-wide workshops on sharing resources and reducing time to activation of clinical trials as well as networking events were included. Collectively, the presentations converged on 3 overarching themes: (1) interception and early-disease biology, (2) development of innovative targeted and immune-based therapies, and (3) the critical role of shared resources and collaborative infrastructure in accelerating translational progress. The unifying theme across disease sites was molecular advances to improve early detection and prevention and to drive therapeutic advancements. Novel findings discussed included candidate precursor cells and mechanisms of high-grade serous ovarian cancer development, therapeutic vaccines and their delivery methods for cervical dysplasia, identification of immune-targetable ovarian cancer antigens, various novel molecularly targeted drugs and immune-based agents for endometrial and ovarian cancers, and approaches to bypass drug resistance. Workshops delineated actionable strategies to further advance gynecologic cancer translational research.<\/jats:p>","DOI":"10.1093\/jnci\/djag319","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:53:40Z","timestamp":1789041220000},"source":"Crossref","is-referenced-by-count":1,"title":["Recent advancements in gynecologic cancer research: a Specialized Programs of Research Excellence investigators meeting report"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-8245","authenticated-orcid":false,"given":"Doris Mangiaracina","family":"Benbrook","sequence":"first","affiliation":[{"name":"University of Oklahoma Harold Hamm Health Campus Department of Obstetrics and Gynecology, , Oklahoma City, OK,","place":["United States"]},{"name":"Stephenson Cancer Center, University of Oklahoma Division of Gynecologic Oncology, , Oklahoma City, OK,","place":["United States"]},{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Levinson","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Department of Gynecology and Obstetrics, , Baltimore, MD,","place":["United States"]},{"name":"Johns Hopkins University\/University of Pennsylvania Ovarian Cancer SPORE , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-2178","authenticated-orcid":false,"given":"Nagarajan","family":"Kannan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Ovarian Cancer SPORE , Rochester, MN, and Phoenix, AZ,","place":["United States"]},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-9171","authenticated-orcid":false,"given":"Bethany N","family":"Hannafon","sequence":"additional","affiliation":[{"name":"University of Oklahoma Harold Hamm Health Campus Department of Obstetrics and Gynecology, , Oklahoma City, OK,","place":["United States"]},{"name":"Stephenson Cancer Center, University of Oklahoma Division of Gynecologic Oncology, , Oklahoma City, OK,","place":["United States"]},{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Kozbor","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center Department of Immunology, , Buffalo, NY,","place":["United States"]},{"name":"Roswell Park\/University of Chicago Ovarian Cancer SPORE , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-7683","authenticated-orcid":false,"given":"Arun","family":"Kanakkanthara","sequence":"additional","affiliation":[{"name":"Mayo Clinic Ovarian Cancer SPORE , Rochester, MN, and Phoenix, AZ,","place":["United States"]},{"name":"Division of Oncology Research, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Chandra","sequence":"additional","affiliation":[{"name":"University of Oklahoma Harold Hamm Health Campus Department of Obstetrics and Gynecology, , Oklahoma City, OK,","place":["United States"]},{"name":"Stephenson Cancer Center, University of Oklahoma Division of Gynecologic Oncology, , Oklahoma City, OK,","place":["United States"]},{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-6929","authenticated-orcid":false,"given":"Marion","family":"Curtis","sequence":"additional","affiliation":[{"name":"Mayo Clinic Ovarian Cancer SPORE , Rochester, MN, and Phoenix, AZ,","place":["United States"]},{"name":"Department of Immunology, Mayo Clinic , Phoenix, AZ,","place":["United States"]},{"name":"Mayo Clinic Comprehensive Cancer Center, Mayo Clinic , Rochester, MN, and Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5574-8783","authenticated-orcid":false,"given":"Nadine","family":"Hempel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Malignant Hematology & Medical Oncology, UPMC Hillman Cancer Center, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]},{"name":"University of Pittsburgh Ovarian Cancer SPORE , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-8990","authenticated-orcid":false,"given":"Kimberly K","family":"Leslie","sequence":"additional","affiliation":[{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]},{"name":"University of New Mexico Division of Molecular Medicine, Department of Internal Medicine, , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-286X","authenticated-orcid":false,"given":"Han","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]},{"name":"MD Anderson Cancer Center Ovarian Cancer SPORE , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Powell","sequence":"additional","affiliation":[{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]},{"name":"Washington University Department of Obstetrics and Gynecology, , Saint Louis, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-5265","authenticated-orcid":false,"given":"Rajani","family":"Rai","sequence":"additional","affiliation":[{"name":"University of Oklahoma Harold Hamm Health Campus Department of Obstetrics and Gynecology, , Oklahoma City, OK,","place":["United States"]},{"name":"Stephenson Cancer Center, University of Oklahoma Division of Gynecologic Oncology, , Oklahoma City, OK,","place":["United States"]},{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-9325","authenticated-orcid":false,"given":"Mara","family":"Steinkamp","sequence":"additional","affiliation":[{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]},{"name":"Department of Pathology, University of New Mexico , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4704-1814","authenticated-orcid":false,"given":"Xiang","family":"Xue","sequence":"additional","affiliation":[{"name":"Route 66 Endometrial Cancer SPORE , Saint Louis, MO; Oklahoma City, OK; and Albuquerque, NM,","place":["United States"]},{"name":"Department of Biochemistry and Molecular Biology, University of New Mexico , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2026110414315711500_djag319-B1","doi-asserted-by":"publisher","first-page":"04155","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J Glob Health"},{"key":"2026110414315711500_djag319-B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ijgo.70279","article-title":"Global determinants of gynecologic cancer incidence and mortality: a cluster-based analysis with predictive insights","volume":"171 Suppl 1","author":"Cuello","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"2026110414315711500_djag319-B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"2026110414315711500_djag319-B4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32120672","article-title":"Diabetes, obesity, and endometrial cancer: a review","volume":"32","author":"Hooks","year":"2025","journal-title":"Curr Oncol"},{"key":"2026110414315711500_djag319-B5","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/j.lanogw.2025.10.001","article-title":"Increasing incidence of endometrial cancer demands global action","volume":"1","author":"Levy","year":"2025","journal-title":"Lancet Obstet Gynecol Womens Health"},{"key":"2026110414315711500_djag319-B6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1055-9965.EPI-24-1422","article-title":"Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States","volume":"34","author":"Wright","year":"2025","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026110414315711500_djag319-B7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ijc.35369","article-title":"Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: the urgent need to address inequalities in cervical cancer","volume":"157","author":"Li","year":"2025","journal-title":"Int J Cancer"},{"key":"2026110414315711500_djag319-B8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ygyno.2024.01.034","article-title":"Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: a 15-year population-based analysis","volume":"184","author":"Somasegar","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2026110414315711500_djag319-B9","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.5306\/wjco.v16.i6.108393","article-title":"Demographic trends in mortality due to ovarian cancer in the United States, 1999-2020","volume":"16","author":"Razaq","year":"2025","journal-title":"World J Clin Oncol"},{"key":"2026110414315711500_djag319-B10","doi-asserted-by":"publisher","first-page":"102385","DOI":"10.1016\/j.ctrv.2022.102385","article-title":"Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials","volume":"106","author":"Monk","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026110414315711500_djag319-B11","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"SpringerPlus"},{"key":"2026110414315711500_djag319-B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1158\/1055-9965.Epi-25-0609","article-title":"Opportunities to avoid invasive cancer by diagnosis and interception of preneoplastic lesions and cancer risk conditions","volume":"35","author":"Pradhan","year":"2026","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026110414315711500_djag319-B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41568-024-00744-0","article-title":"Defining precancer: a grand challenge for the cancer community","volume":"24","author":"Faupel-Badger","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026110414315711500_djag319-B14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/2159-8290.CD-24-0015","article-title":"Advancing cancer interception","volume":"14","author":"Domchek","year":"2024","journal-title":"Cancer Discov"},{"key":"2026110414315711500_djag319-B15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1158\/1940-6207.CAPR-24-0558","article-title":"From combination early detection to multicancer testing: shifting cancer care toward proactive prevention and interception","volume":"18","author":"Albini","year":"2025","journal-title":"Cancer Prev Res"},{"key":"2026110414315711500_djag319-B16","article-title":"A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer","author":"Ritting","year":"2025:","journal-title":"bioRxiv"},{"key":"2026110414315711500_djag319-B17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41568-024-00754-y","article-title":"Emerging strategies to investigate the biology of early cancer","volume":"24","author":"Zhou","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026110414315711500_djag319-B18","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-025-57430-4","article-title":"DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"2026110414315711500_djag319-B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2020.09.002","article-title":"Next-generation analytics for omics data","volume":"39","author":"Li","year":"2021","journal-title":"Cancer Cell"},{"key":"2026110414315711500_djag319-B20","doi-asserted-by":"publisher","first-page":"848682","DOI":"10.3389\/fcell.2022.848682","article-title":"SHetA2 attack on mortalin and colleagues in cancer therapy and prevention","volume":"10","author":"Benbrook","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026110414315711500_djag319-B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102322","article-title":"Utility and mechanism of SHetA2 and paclitaxel for treatment of endometrial cancer","volume":"13","author":"Chandra","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026110414315711500_djag319-B22","doi-asserted-by":"publisher","first-page":"e05592 (1-23)","DOI":"10.1002\/advs.202505592","article-title":"Mortalin and PINK1\/parkin-mediated mitophagy represent ovarian cancer-selective targets for drug development","volume":"12","author":"Chandra","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"2026110414315711500_djag319-B23","doi-asserted-by":"publisher","first-page":"958536","DOI":"10.3389\/fonc.2022.958536","article-title":"Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2","volume":"12","author":"Rai","year":"2022","journal-title":"Front Oncol"},{"key":"2026110414315711500_djag319-B24","doi-asserted-by":"publisher","DOI":"10.1101\/2025.11.18.689080","article-title":"Curcumin analogues trigger HMOX1-mediated ferroptosis to halt endometrial cancer growth","author":"Wu","year":"2025","journal-title":"bioRxiv"},{"key":"2026110414315711500_djag319-B25","doi-asserted-by":"publisher","first-page":"102329","DOI":"10.1016\/j.redox.2022.102329","article-title":"HuR-dependent SOD2 protein synthesis is an early adaptation to anchorage-independence","volume":"53","author":"Kim","year":"2022","journal-title":"Redox Biol"},{"key":"2026110414315711500_djag319-B26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41388-019-1097-7","article-title":"Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells","volume":"39","author":"Kim","year":"2020","journal-title":"Oncogene"},{"key":"2026110414315711500_djag319-B27","doi-asserted-by":"publisher","first-page":"101051","DOI":"10.1016\/j.redox.2018.11.009","article-title":"GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment","volume":"25","author":"Worley","year":"2019","journal-title":"Redox Biol"},{"key":"2026110414315711500_djag319-B28","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-14-3799","article-title":"Mitochondrial superoxide dismutase has a protumorigenic role in ovarian clear cell carcinoma","volume":"75","author":"Hemachandra","year":"2015","journal-title":"Cancer Res"},{"key":"2026110414315711500_djag319-B29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1158\/1541-7786.MCR-12-0478","article-title":"Acquisition of the metastatic phenotype is accompanied by H2O2-dependent activation of the p130Cas signaling complex","volume":"11","author":"Hempel","year":"2013","journal-title":"Mol Cancer Res"},{"key":"2026110414315711500_djag319-B30","doi-asserted-by":"publisher","first-page":"eadt8706","DOI":"10.1126\/scitranslmed.adt8706","article-title":"Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer","volume":"18","author":"Duffield","year":"2026","journal-title":"Sci Transl Med"},{"key":"2026110414315711500_djag319-B31","doi-asserted-by":"publisher","first-page":"1061761","DOI":"10.3389\/fimmu.2023.1061761","article-title":"Evaluation of immunotherapy efficacy in gynecologic cancer","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"2026110414315711500_djag319-B32","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"2026110414315711500_djag319-B33","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"2026110414315711500_djag319-B34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2021.01.025","article-title":"Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced\/recurrent endometrial cancer: an NRG Oncology study","volume":"161","author":"Leslie","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026110414315711500_djag319-B35","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1200\/JCO.21.02506","article-title":"TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"40","author":"Thiel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026110414315711500_djag319-B36","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1124\/jpet.124.002223","article-title":"Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer","volume":"392","author":"Elayapillai","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"2026110414315711500_djag319-B37","doi-asserted-by":"publisher","first-page":"eads7405","DOI":"10.1126\/sciadv.ads7405","article-title":"Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer","volume":"11","author":"Raja","year":"2025","journal-title":"Sci Adv"},{"key":"2026110414315711500_djag319-B38","doi-asserted-by":"publisher","first-page":"2460276","DOI":"10.1080\/2162402X.2025.2460276","article-title":"Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer","volume":"14","author":"Bassoy","year":"2025","journal-title":"Oncoimmunology"},{"key":"2026110414315711500_djag319-B39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2026110414315711500_djag319-B40","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-23-2570","article-title":"Bridging the gap from bench to bedside: a call for in vivo preclinical models to advance endometrial cancer and cervical cancer immuno-oncology research","volume":"30","author":"Chambers","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag319\/71103718\/djag319.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag319\/71103718\/djag319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:32:02Z","timestamp":1793820722000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag319\/8799003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag319","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"djag319"}}